Shift of the f/t-PSA quotient in relation to renal insufficiency: Consequences for the early detection of prostate carcinoma in patients with terminal renal failure

Anticancer Research

Volumn 27, Issue 4 A, 2007, Pages 1945-1948

  Fischer, Kersten ^a,b   Hamza, Amir ^a   Wicht, Andreas ^a   Loertzer, Hagen ^a   Fornara, Paolo ^a  

^a MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

^b MARTIN LUTHER UNIVERSITÄT HALLE WITTENBERG   (Germany)

Author keywords

Free PSA; Percent free PSA; PSA; Renal failure; Renal transplantation

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

CONFERENCE PAPER; CONTROLLED STUDY; DIALYSIS; EARLY DIAGNOSIS; HUMAN; KIDNEY FAILURE; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CARCINOMA;

HUMANS; KIDNEY FAILURE; KIDNEY TRANSPLANTATION; MALE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; SENSITIVITY AND SPECIFICITY;

EID: 34250699391     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (23)

1. Cormier L, Lechevallier E, Barrou B, Benoit G, Bensadoun H, Boudjema K, Descottes JL, Dore B, Guy L, Malavaud B, Martin X, Patard JJ, Petit J and Salomon L: Diagnosis and treatment of prostate cancers in renal transplant recipients. Transplantation 75: 237-239, 2003.
2. Noldus J and Huland H: Treatment of localized prostate cancer. Onkologie 26(Suppl 4): 6-12, 2003.
3. Noldus J, Palisaar RJ, Huland H: Treatment of prostate cancer - the clinical use of radical prostatectomy. EAU Update Series 1(1): 16-22, 2003.
4. Hafron J, Fogarty JD, Wiesen A and Melman A: Surgery for localized prostate cancer after renal transplantation. BJU Int 95: 319-322, 2005.
5. Luboldt HJ, Swoboda A, Boergermann C, Fornara P and Ruebben H: Early Detection Project Group of the German Society of Urology: Clinical usefulness of free PSA in early detection of prostate cancer. Onkologie 24(1): 33-37, 2001.
6. Catalona WJ, Partin AW, Slawin KM, Brawer MK, Patel A, Flanigan RC, Richie JP, deKernion JB, Walsh PC, Scardino PT, Lange PH, Herschman JD, Subong ENP, Petteway JC, Parson RE, Loveland KG, Gasior GH and Southwick PC: A multicenter clinical trial evaluation of free PSA in the differentiation of prostate cancer from benign disease. J Urol Pt 2 157(111): abstract 434, 1997.
7. Finne P, Auvinen A, Aro J, Juusela H, Maattanen L, Rannikko S, Hakama M, Tammela TL and Stenman UH: Estimation of prostate cancer risk on the basis of total and free prostate-specific antigen, prostate volume and digital rectal examination. Eur Urol 41(6): 619-626, 2002.
8. Hugosson J, Aus G, Bergdahl S, Fernlund P, Frosing R, Lodding P, Pihl CG and Lilja H: Population-based screening for prostate cancer by measuring free and total serum prostate-specific antigen in Sweden. BJU Int 92(Suppl 2): 39-43, 2003.
9. Kabalin JN and Hornberger JC: Prostate-specific antigen is not excreted by human kidney or eliminated by routine hemodialysis. Urology 37: 308-310, 1991.
10. Monath JR, Burkart JM, Freedman BI, Pittaway DE, Russell GB and Assimos DG: Effects of hemodialysis on prostate-specific antigen. Urology 42: 398-400, 1993.
11. Douville P and Tiberi M: Effect of terminal renal failure on the ratio of free to total prostate-specific antigen. Tumour Biol 19: 113-117, 1998.
12. Sasagawa I, Kubota Y, Hayami S, Adachi M, Nakada T, Miura H and Imai K: Serum levels of total and free prostate specific antigen in men on hemodialysis. J Urol 160(1): 83-85, 1998.
13. Djavan B, Shariat S, Ghawidel K, Guven-Marberger K, Remzi M, Kovarik J, Hoerl WH and Marberger M: Impact of chronic dialysis on serum PSA, free PSA, and free/total PSA ratio: is prostate cancer detection compromised in patients receiving long-term dialysis? Urology 53: 1169-1174, 1999.
14. Wolff JM, Ting O, Borchers H, Rohde D and Jakse G: Serum levels of prostate-specific antigen in men on hemodialysis. Anticancer Res 20(6D): 5191-5193, 2000.
15. Danisman A, Kilic S, Kukul E, Yakupoglu G, Guntekin E, Baykara M and Sevuk M: Do renal failure and hemodialysis have any effect on the elimination of free and total prostate-specific antigen? Eur Urol 37(5): 579-581, 2000.
16. Tzanakis I, Kazoulis S, Girousis N, Kagia S, Spandidakis V, Karefillakis N, Georgila M, Cristoulakis I, Hatzilias P and Kallivretakis N: Prostate-specific antigen in hemodialysis patients and the influence of dialysis in its levels. Nephron 90: 230-233, 2002.
17. Brunn L, Bjork T, Lilja H, Becker C, Gustafsson O and Christensson A: Percent-free prostate specific antigen is elevated in men on haemodialysis or peritoneal dialysis treatment. Nephrol Dial Transplant 18: 598-603, 2003.
18. Bruun L, Ekberg H, Bjork T, Lilja H, Hoglund P and Christensson A: Rapid elimination by glomerular filtration of free prostate specific antigen and human kallikrein 2 after renal transplantation. J Urol 171(4): 1432-1435, 2004.
19. Lövgren J, Rajakoski K, Karp M, Lundwall A and Lilja H: Activation of the zymogen form of prostate-specific antigen by human glandular kallikrein 2. Biochem Biophys Res Commun 238: 549-555, 1997.
20. Takayama TK, Fujikawa K and Davie EW: Characterization of the precursor of prostate-specific antigen. Activation by trypsin and by human glandular kallikrein. J Biol Chem 272: 21582-21582, 1997.
21. Lein M, Stephan C, Jung K, Schnorr D and Loening SA: Molekulare Formen des prostataspezifischen Antigens und des humanen Kallikreins 2 als mögliche Indikatoren in der Prostatakarzinomdiagnostik. Urologe [A] 39: 313-323, 2000 (in German).
22. Honda SA, Goldstein AP, Morita T, Sugiyama C, Cody L, Rios CN and Bhagavan NV: Prostate-specific antigen concentrations in serum in acute illnesses. Clin Chem 42: 1785-1788, 1996.
23. Kilic S, Yalcinkaya S, Guntekin E, Kukul E, Deger N and Sevuk M: Determination of the site of metabolism of total, free and complexed prostate-specific antigen. Urology 52: 470-473, 1998.